Acknowledgements
We thank all patients and their relatives for being a part of the trial. Hengrui Pharmaceuticals supplied Camrelizumab. We thank Drs. Ming Lu, Shaowei Sang, Xiaorong Yang, Yuan Zhang, Hao Chen, and Tongchao Zhang in the Clinical Research Center of Shandong University for their assistance in statistical analysis. We thank Alexandra H. Marshall (Marshall Medical Communications) for editing this manuscript. This work was supported by the National Natural Science Foundation of China (82173305, L.L.), Natural Science Foundation of Shandong Province (ZR2017MH005, L.L.), and Foundation of Shandong University Clinical Research Center (2020SDUCRCC011, S.L.). The funders had no role in study design, data collection and analysis, or manuscript writing.